Key points from article :
Applied BioMath, a leader in systems pharmacology and mechanistic modelling, has announced a collaboration with BYOMass Inc., a preclinical-stage pharmaceutical company targeting the TGF-ß superfamily to address chronic diseases. This partnership will focus on using Applied BioMath’s advanced modelling techniques to guide the development of BYOMass's therapeutic candidates.
BYOMass CEO Dr. Margaret Jackson emphasized the value of Applied BioMath’s expertise in identifying optimal therapeutic properties and platforms. The collaboration aims to streamline the identification of lead candidates and support the design of future studies, accelerating BYOMass’s progress toward developing effective treatments.
Applied BioMath’s approach integrates biological insights, therapeutic mechanisms, and proprietary algorithms to create tailored models that simulate drug behavior and disease interactions. According to Applied BioMath CEO Dr. John Burke, their work with early-stage companies helps ensure therapies are designed to be best in class. This partnership is expected to advance BYOMass’s efforts to address significant unmet medical needs in chronic disease treatment.
